Tmod CAR T-Cell Therapy Offers Precise Targeting of Solid Tumors
The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.
CAR T-Cell Therapy Plus Amplifying Vaccine Shows Initial Safety, Efficacy in Solid Tumors
Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.
Insights into Brexucabtagene Autoleucel R/R B-ALL Approval: Bijal Shah, MD
The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
TCR T-Cell Therapy Shows Efficacy Across Solid Tumor Types
Data from the IMA203 trial were presented at the SITC 2021 annual meeting.
Advancing Natural Killer Cell Therapies for Hematologic Malignancies
Sonny Hsiao, PhD, chief executive officer, president and cofounder, Acepodia, discussed the company’s future research and plans.
Cilta-Cel Safety Profile in Multiple Myeloma: Adam D. Cohen, MD
The director of Myeloma Immunotherapy at University of Pennsylvania discussed ciltacabtagene autoleucel's safety profile.
Photoreceptor Precursor Cells' Potential to Treat Inherited Retinal Diseases
Investigators are planning a first-in-man clinical trial for photoreceptor precursor transplant in Singapore.
Gavo-Cel to Be Evaluated With Nivolumab, Ipilimumab for Solid Tumors
TCR² Therapeutics is collaborating with Bristol Myers Squibb to evaluate combination therapies in a phase 2 trial.
Potential of NK Cells in Multiple Myeloma: Nina Shah, MD
The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.
Gene Therapy Well-Tolerated in Fabry Disease
Primary efficacy data released by Sangamo Therapeutics showed that above normal α-Gal A activity was maintained for up to a year after treatment.
Socioeconomic Factors Affect Stem Cell Transplant in Mantle Cell Lymphoma
Yazeed Sawalha, MD, hematologist, Ohio State University Comprehensive Cancer Center, discussed how socioeconomic factors can affect use of ASCT in mantle cell lymphoma.
Challenges in Developing Gene Therapy for AADC Deficiency: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed the challenges of working with a rare disease.
Autologous HSCT's Role in the Mantle Cell Lymphoma Treatment Landscape
Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma.
Developing Gene Therapies for Rare Diseases
The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s lead programs and future plans.
New Project Aims to Increase CAR T Safety, Availability
A new project is manufacturing a “purified” version of CAR-T-cells currently used to treat types of lymphoma and leukemia.
Real-World Efficacy of Brexucabtagene Autoleucel in Mantle Cell Lymphoma: Luhua Wang, MD
The professor from University of Texas MD Anderson Cancer Center discussed the real-world efficacy of the first CAR T therapy for the treatment of mantle cell lymphoma.
GeneTherapyLive’s Weekly Rewind – November 5, 2021
Review top news and interview highlights from the week ending November 5, 2021.
CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MD
The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Novel Therapies Reduce the Need for Chemotherapy in Leukemias and Lymphomas
Dipenkumar Modi, MD, discussed novel treatment options in leukemias and lymphomas.
Gene Therapies Show Efficacy in Fabry Disease, Choroideremia
4D Molecular Therapeutics announced positive data from trials assessing 2 of their gene therapies.
Future Research With NK and CAR T Therapy in Multiple Myeloma: Irene Ghobrial, MD
The director at Dana-Farber Cancer Institute discussed future efforts to prevent the development of multiple myeloma.
Tisagenlecleucel Granted Priority Review for R/R Follicular Lymphoma
The FDA also accepted a Type II Variation for the use of tisagenlecleucel in patients with R/R FL following 2 prior lines of treatment.
Improving Cell Therapy Manufacturing Through Strategic Partnerships
Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the challenges of manufacturing cell therapies.
FDA Extends Cilta-Cel BLA PDUFA Date for R/R Multiple Myeloma
The FDA has pushed cilta-cel's BLA PDUFA date back by almost 4 months.
Improving Outcomes in AADC Deficiency With Gene Therapy: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed further research he would like to do with the gene therapy PTC-AADC.
Cell Therapy Cancer Vaccine Shows Promise for Progression-Free Survival in Metastatic Pancreatic Cancer
The vaccination therapy improved progression-free survival by 3.1 months over standard care in 1 patient treated.
Personalized Vaccine-Based Therapy for Multiple Myeloma: Nina Shah, MD
The hematologist/oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential of vaccine-based therapies in multiple myeloma.
Rare Disease Consortium to Focus on Optimizing AAV Gene Therapies
Partners in the Bespoke Gene Therapy Consortium include the NIH, FDA, private companies such as Pfizer and Biogen, and non-profits.
Efficient Gene Editing in Monogenic Diseases
André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.
Cell Therapy May Yield Deep Remissions in Multiple Myeloma
Ide-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
